Venetoclax (VEN) in combination with hypomethylating agents (HMAs) has been established as the standard of care for older or unfit patients (pts) with newly diagnosed acute myeloid leukemia (AML). This regimen is also increasingly used in the relapsed/refractory (R/R) setting. In the VIALE-A study, treatment was given until progression. However, the optimal duration of therapy in pts achieving a complete response remains undefined, and treatment discontinuation in such cases is an emerging area of interest in clinical practice. Recent retrospective studies have begun to explore the outcomes of VEN discontinuation in pts in sustained remission, suggesting that treatment-free remission (TFR) may be feasible in selected cases (Chua et al Blood Adv. 2022; Garciaz et al Am J Hematol. 2024). Furthermore, specific molecular profiles predictive of response to VENbased regimens are increasingly recognized and may help identify pts eligible for safe treatment discontinuation, paving the way for more personalized, time-limited treatment strategies
P054 | Discontinuation of venetoclax-based therapies in molecularly selected patients with acute myeloid leukemia in complete remission / Ciolli, G.. - In: HAEMATOLOGICA. - ISSN 1592-8721. - ELETTRONICO. - 111:(2026), pp. 0-0. [10.3324/haematol.2026.s1.119]
P054 | Discontinuation of venetoclax-based therapies in molecularly selected patients with acute myeloid leukemia in complete remission
Ciolli Gaia;A. M. Vannucchi
2026
Abstract
Venetoclax (VEN) in combination with hypomethylating agents (HMAs) has been established as the standard of care for older or unfit patients (pts) with newly diagnosed acute myeloid leukemia (AML). This regimen is also increasingly used in the relapsed/refractory (R/R) setting. In the VIALE-A study, treatment was given until progression. However, the optimal duration of therapy in pts achieving a complete response remains undefined, and treatment discontinuation in such cases is an emerging area of interest in clinical practice. Recent retrospective studies have begun to explore the outcomes of VEN discontinuation in pts in sustained remission, suggesting that treatment-free remission (TFR) may be feasible in selected cases (Chua et al Blood Adv. 2022; Garciaz et al Am J Hematol. 2024). Furthermore, specific molecular profiles predictive of response to VENbased regimens are increasingly recognized and may help identify pts eligible for safe treatment discontinuation, paving the way for more personalized, time-limited treatment strategies| File | Dimensione | Formato | |
|---|---|---|---|
|
13314-Article Text-90542-1-10-20260304.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
1.03 MB
Formato
Adobe PDF
|
1.03 MB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.



